APO Research
Talk to an analyst

APO RESEARCH · REPORT

Intravenous (IV) Iron Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Intravenous (IV) Iron Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

26 December 2025188 pages

Choose your research edition.

Industry ResearchIntravenous (IV) Iron Drugs Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Intravenous (IV) Iron Drugs Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal Intravenous (IV) Iron Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Intravenous (IV) Iron Drugs Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Intravenous (IV) Iron Drugs Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Intravenous (IV) Iron Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Intravenous (IV) Iron Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Intravenous (IV) Iron Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Intravenous (IV) Iron Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Intravenous (IV) Iron Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Intravenous (IV) Iron Drugs include Takeda Pharmaceutical, Sanofi US, Pharmacosmos, Luitpold Pharmaceuticals, Dalichi Sankyo, AMAG Pharmaceuticals and Allergan, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Intravenous (IV) Iron Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Intravenous (IV) Iron Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Intravenous (IV) Iron Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Intravenous (IV) Iron Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Intravenous (IV) Iron Drugs Segment by Company

Takeda Pharmaceutical

Sanofi US

Pharmacosmos

Luitpold Pharmaceuticals

Dalichi Sankyo

AMAG Pharmaceuticals

Allergan

Intravenous (IV) Iron Drugs Segment by Type

Ferric Carboxymaltose

Iron Dextran

Iron Sucrose

Others

Intravenous (IV) Iron Drugs Segment by Application

Gynecology & Obstetrics

Nephrology

Gastroenterology

Cardiology

Oncology

Others

Intravenous (IV) Iron Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Intravenous (IV) Iron Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Intravenous (IV) Iron Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Intravenous (IV) Iron Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Intravenous (IV) Iron Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Intravenous (IV) Iron Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Intravenous (IV) Iron Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Intravenous (IV) Iron Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Intravenous (IV) Iron Drugs Industry Trends Table 2. Intravenous (IV) Iron Drugs Industry Drivers Table 3. Intravenous (IV) Iron Drugs Industry Opportunities and Challenges Table 4. Intravenous (IV) Iron Drugs Industry Restraints Table 5. Global Intravenous (IV) Iron Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Intravenous (IV) Iron Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Intravenous (IV) Iron Drugs Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Intravenous (IV) Iron Drugs Sales Market Share by Manufacturers Table 9. Global Intravenous (IV) Iron Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Intravenous (IV) Iron Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Intravenous (IV) Iron Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Intravenous (IV) Iron Drugs Manufacturers, Product Type & Application Table 13. Global Intravenous (IV) Iron Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Intravenous (IV) Iron Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Ferric Carboxymaltose Table 17. Major Manufacturers of Iron Dextran Table 18. Major Manufacturers of Iron Sucrose Table 19. Major Manufacturers of Others Table 20. Global Intravenous (IV) Iron Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Intravenous (IV) Iron Drugs Sales by Type (2021-2026) & (K Units) Table 22. Global Intravenous (IV) Iron Drugs Sales by Type (2027-2032) & (K Units) Table 23. Global Intravenous (IV) Iron Drugs Sales Market Share by Type (2021-2026) Table 24. Global Intravenous (IV) Iron Drugs Sales Market Share by Type (2027-2032) Table 25. Global Intravenous (IV) Iron Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 26. Global Intravenous (IV) Iron Drugs Revenue by Type (2021-2026) & (K Units) Table 27. Global Intravenous (IV) Iron Drugs Revenue by Type (2027-2032) & (K Units) Table 28. Global Intravenous (IV) Iron Drugs Revenue Market Share by Type (2021-2026) Table 29. Global Intravenous (IV) Iron Drugs Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Gynecology & Obstetrics Table 31. Major Manufacturers of Nephrology Table 32. Major Manufacturers of Gastroenterology Table 33. Major Manufacturers of Cardiology Table 34. Major Manufacturers of Oncology Table 35. Major Manufacturers of Others Table 36. Global Intravenous (IV) Iron Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Intravenous (IV) Iron Drugs Sales by Application (2021-2026) & (K Units) Table 38. Global Intravenous (IV) Iron Drugs Sales by Application (2027-2032) & (K Units) Table 39. Global Intravenous (IV) Iron Drugs Sales Market Share by Application (2021-2026) Table 40. Global Intravenous (IV) Iron Drugs Sales Market Share by Application (2027-2032) Table 41. Global Intravenous (IV) Iron Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 42. Global Intravenous (IV) Iron Drugs Revenue by Application (2021-2026) & (K Units) Table 43. Global Intravenous (IV) Iron Drugs Revenue by Application (2027-2032) & (K Units) Table 44. Global Intravenous (IV) Iron Drugs Revenue Market Share by Application (2021-2026) Table 45. Global Intravenous (IV) Iron Drugs Revenue Market Share by Application (2027-2032) Table 46. Global Intravenous (IV) Iron Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global Intravenous (IV) Iron Drugs Sales by Region (2021-2026) & (K Units) Table 48. Global Intravenous (IV) Iron Drugs Sales Market Share by Region (2021-2026) Table 49. Global Intravenous (IV) Iron Drugs Sales Forecasted by Region (2027-2032) & (K Units) Table 50. Global Intravenous (IV) Iron Drugs Sales Forecasted Market Share by Region (2027-2032) Table 51. North America Intravenous (IV) Iron Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. North America Intravenous (IV) Iron Drugs Sales by Country (2021-2026) & (K Units) Table 53. North America Intravenous (IV) Iron Drugs Sales by Country (2027-2032) & (K Units) Table 54. Europe Intravenous (IV) Iron Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Europe Intravenous (IV) Iron Drugs Sales by Country (2021-2026) & (K Units) Table 56. Europe Intravenous (IV) Iron Drugs Sales by Country (2027-2032) & (K Units) Table 57. Asia Pacific Intravenous (IV) Iron Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Asia Pacific Intravenous (IV) Iron Drugs Sales by Country (2021-2026) & (K Units) Table 59. Asia Pacific Intravenous (IV) Iron Drugs Sales by Country (2027-2032) & (K Units) Table 60. South America, Middle East and Africa Intravenous (IV) Iron Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 61. South America, Middle East and Africa Intravenous (IV) Iron Drugs Sales by Country (2021-2026) & (K Units) Table 62. South America, Middle East and Africa Intravenous (IV) Iron Drugs Sales by Country (2027-2032) & (K Units) Table 63. Global Intravenous (IV) Iron Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 64. Global Intravenous (IV) Iron Drugs Revenue by Region (2021-2026) & (US$ Million) Table 65. Global Intravenous (IV) Iron Drugs Revenue by Region (2027-2032) & (US$ Million) Table 66. Global Intravenous (IV) Iron Drugs Revenue Market Share by Region (2021-2026) Table 67. Global Intravenous (IV) Iron Drugs Revenue Market Share by Region (2027-2032) Table 68. Takeda Pharmaceutical Company Information Table 69. Takeda Pharmaceutical Business Overview Table 70. Takeda Pharmaceutical Intravenous (IV) Iron Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Takeda Pharmaceutical Intravenous (IV) Iron Drugs Product Portfolio Table 72. Takeda Pharmaceutical Recent Development Table 73. Sanofi US Company Information Table 74. Sanofi US Business Overview Table 75. Sanofi US Intravenous (IV) Iron Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Sanofi US Intravenous (IV) Iron Drugs Product Portfolio Table 77. Sanofi US Recent Development Table 78. Pharmacosmos Company Information Table 79. Pharmacosmos Business Overview Table 80. Pharmacosmos Intravenous (IV) Iron Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Pharmacosmos Intravenous (IV) Iron Drugs Product Portfolio Table 82. Pharmacosmos Recent Development Table 83. Luitpold Pharmaceuticals Company Information Table 84. Luitpold Pharmaceuticals Business Overview Table 85. Luitpold Pharmaceuticals Intravenous (IV) Iron Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Luitpold Pharmaceuticals Intravenous (IV) Iron Drugs Product Portfolio Table 87. Luitpold Pharmaceuticals Recent Development Table 88. Dalichi Sankyo Company Information Table 89. Dalichi Sankyo Business Overview Table 90. Dalichi Sankyo Intravenous (IV) Iron Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Dalichi Sankyo Intravenous (IV) Iron Drugs Product Portfolio Table 92. Dalichi Sankyo Recent Development Table 93. AMAG Pharmaceuticals Company Information Table 94. AMAG Pharmaceuticals Business Overview Table 95. AMAG Pharmaceuticals Intravenous (IV) Iron Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. AMAG Pharmaceuticals Intravenous (IV) Iron Drugs Product Portfolio Table 97. AMAG Pharmaceuticals Recent Development Table 98. Allergan Company Information Table 99. Allergan Business Overview Table 100. Allergan Intravenous (IV) Iron Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Allergan Intravenous (IV) Iron Drugs Product Portfolio Table 102. Allergan Recent Development Table 103. Key Raw Materials Table 104. Raw Materials Key Suppliers Table 105. Intravenous (IV) Iron Drugs Distributors List Table 106. Intravenous (IV) Iron Drugs Customers List Table 107. Research Programs/Design for This Report Table 108. Authors List of This Report Table 109. Secondary Sources Table 110. Primary Sources List of Figures Figure 1. Intravenous (IV) Iron Drugs Product Image Figure 2. Global Intravenous (IV) Iron Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Intravenous (IV) Iron Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Intravenous (IV) Iron Drugs Sales (2021-2032) & (K Units) Figure 5. Global Intravenous (IV) Iron Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Intravenous (IV) Iron Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Ferric Carboxymaltose Image Figure 9. Iron Dextran Image Figure 10. Iron Sucrose Image Figure 11. Others Image Figure 12. Global Intravenous (IV) Iron Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Intravenous (IV) Iron Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Intravenous (IV) Iron Drugs Sales Market Share by Type (2021-2032) Figure 15. Global Intravenous (IV) Iron Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Intravenous (IV) Iron Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Intravenous (IV) Iron Drugs Revenue Market Share by Type (2021-2032) Figure 18. Gynecology & Obstetrics Image Figure 19. Nephrology Image Figure 20. Gastroenterology Image Figure 21. Cardiology Image Figure 22. Oncology Image Figure 23. Others Image Figure 24. Global Intravenous (IV) Iron Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Intravenous (IV) Iron Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 26. Global Intravenous (IV) Iron Drugs Sales Market Share by Application (2021-2032) Figure 27. Global Intravenous (IV) Iron Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 28. Global Intravenous (IV) Iron Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 29. Global Intravenous (IV) Iron Drugs Revenue Market Share by Application (2021-2032) Figure 30. North America Intravenous (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 31. North America Intravenous (IV) Iron Drugs Sales Market Share by Country (2021-2032) Figure 32. U.S. Intravenous (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Canada Intravenous (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Mexico Intravenous (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe Intravenous (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Europe Intravenous (IV) Iron Drugs Sales Market Share by Country (2021-2032) Figure 37. Germany Intravenous (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 38. France Intravenous (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 39. U.K. Intravenous (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Italy Intravenous (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Netherlands Intravenous (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific Intravenous (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Asia Pacific Intravenous (IV) Iron Drugs Sales Market Share by Country (2021-2032) Figure 44. China Intravenous (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Japan Intravenous (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South Korea Intravenous (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Southeast Asia Intravenous (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 48. India Intravenous (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Australia Intravenous (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa Intravenous (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South America, Middle East and Africa Intravenous (IV) Iron Drugs Sales Market Share by Country (2021-2032) Figure 52. Brazil Intravenous (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 53. South Africa Intravenous (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Saudi Arabia Intravenous (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Turkey Intravenous (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Argentina Intravenous (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 57. UAE Intravenous (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Egypt Intravenous (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Chile Intravenous (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 60. Global Intravenous (IV) Iron Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Global Intravenous (IV) Iron Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 62. North America Intravenous (IV) Iron Drugs Revenue (2021-2032) & (US$ Million) Figure 63. North America Intravenous (IV) Iron Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Europe Intravenous (IV) Iron Drugs Revenue (2021-2032) & (US$ Million) Figure 65. Europe Intravenous (IV) Iron Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Asia-Pacific Intravenous (IV) Iron Drugs Revenue (2021-2032) & (US$ Million) Figure 67. Asia-Pacific Intravenous (IV) Iron Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. South America, Middle East and Africa Intravenous (IV) Iron Drugs Revenue (2021-2032) & (US$ Million) Figure 69. South America, Middle East and Africa Intravenous (IV) Iron Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. Intravenous (IV) Iron Drugs Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Intravenous (IV) Iron Drugs Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Ferric Carboxymaltose
  • Iron Dextran
  • Iron Sucrose
  • Others
Applications
  • Gynecology & Obstetrics
  • Nephrology
  • Gastroenterology
  • Cardiology
  • Oncology
  • Others
Companies covered
  • Takeda Pharmaceutical
  • Sanofi US
  • Pharmacosmos
  • Luitpold Pharmaceuticals
  • Dalichi Sankyo
  • AMAG Pharmaceuticals
  • Allergan

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Intravenous (IV) Iron Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Intravenous (IV) Iron Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Intravenous (IV) Iron Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Intravenous (IV) Iron Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Intravenous (IV) Iron Drugs Market Dynamics
  1. 2.1 Intravenous (IV) Iron Drugs Industry Trends
  2. 2.2 Intravenous (IV) Iron Drugs Industry Drivers
  3. 2.3 Intravenous (IV) Iron Drugs Industry Opportunities and Challenges
  4. 2.4 Intravenous (IV) Iron Drugs Industry Restraints
3 Intravenous (IV) Iron Drugs Market by Manufacturers
  1. 3.1 Global Intravenous (IV) Iron Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Intravenous (IV) Iron Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Intravenous (IV) Iron Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Intravenous (IV) Iron Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Intravenous (IV) Iron Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Intravenous (IV) Iron Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Intravenous (IV) Iron Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Intravenous (IV) Iron Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Intravenous (IV) Iron Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Intravenous (IV) Iron Drugs Tier 1, Tier 2, and Tier 3
4 Intravenous (IV) Iron Drugs Market by Type
  1. 4.1 Intravenous (IV) Iron Drugs Type Introduction
  2. 4.1.1 Ferric Carboxymaltose
  3. 4.1.2 Iron Dextran
  4. 4.1.3 Iron Sucrose
  5. 4.1.4 Others
  6. 4.2 Global Intravenous (IV) Iron Drugs Sales by Type
  7. 4.2.1 Global Intravenous (IV) Iron Drugs Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Intravenous (IV) Iron Drugs Sales by Type (2021-2032)
  9. 4.2.3 Global Intravenous (IV) Iron Drugs Sales Market Share by Type (2021-2032)
  10. 4.3 Global Intravenous (IV) Iron Drugs Revenue by Type
  11. 4.3.1 Global Intravenous (IV) Iron Drugs Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Intravenous (IV) Iron Drugs Revenue by Type (2021-2032)
  13. 4.3.3 Global Intravenous (IV) Iron Drugs Revenue Market Share by Type (2021-2032)
5 Intravenous (IV) Iron Drugs Market by Application
  1. 5.1 Intravenous (IV) Iron Drugs Application Introduction
  2. 5.1.1 Gynecology & Obstetrics
  3. 5.1.2 Nephrology
  4. 5.1.3 Gastroenterology
  5. 5.1.4 Cardiology
  6. 5.1.5 Oncology
  7. 5.1.6 Others
  8. 5.2 Global Intravenous (IV) Iron Drugs Sales by Application
  9. 5.2.1 Global Intravenous (IV) Iron Drugs Sales by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Intravenous (IV) Iron Drugs Sales by Application (2021-2032)
  11. 5.2.3 Global Intravenous (IV) Iron Drugs Sales Market Share by Application (2021-2032)
  12. 5.3 Global Intravenous (IV) Iron Drugs Revenue by Application
  13. 5.3.1 Global Intravenous (IV) Iron Drugs Revenue by Application (2021 VS 2025 VS 2032)
  14. 5.3.2 Global Intravenous (IV) Iron Drugs Revenue by Application (2021-2032)
  15. 5.3.3 Global Intravenous (IV) Iron Drugs Revenue Market Share by Application (2021-2032)
6 Global Intravenous (IV) Iron Drugs Sales by Region
  1. 6.1 Global Intravenous (IV) Iron Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Intravenous (IV) Iron Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Intravenous (IV) Iron Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Intravenous (IV) Iron Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Intravenous (IV) Iron Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Intravenous (IV) Iron Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Intravenous (IV) Iron Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Intravenous (IV) Iron Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Intravenous (IV) Iron Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Intravenous (IV) Iron Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Intravenous (IV) Iron Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Intravenous (IV) Iron Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Intravenous (IV) Iron Drugs Revenue by Region
  1. 7.1 Global Intravenous (IV) Iron Drugs Revenue by Region
  2. 7.1.1 Global Intravenous (IV) Iron Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Intravenous (IV) Iron Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Intravenous (IV) Iron Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Intravenous (IV) Iron Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Intravenous (IV) Iron Drugs Revenue (2021-2032)
  8. 7.2.2 North America Intravenous (IV) Iron Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Intravenous (IV) Iron Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Intravenous (IV) Iron Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Intravenous (IV) Iron Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Intravenous (IV) Iron Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Intravenous (IV) Iron Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Intravenous (IV) Iron Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceutical
  2. 8.1.1 Takeda Pharmaceutical Company Information
  3. 8.1.2 Takeda Pharmaceutical Business Overview
  4. 8.1.3 Takeda Pharmaceutical Intravenous (IV) Iron Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceutical Intravenous (IV) Iron Drugs Product Portfolio
  6. 8.1.5 Takeda Pharmaceutical Recent Developments
  7. 8.2 Sanofi US
  8. 8.2.1 Sanofi US Company Information
  9. 8.2.2 Sanofi US Business Overview
  10. 8.2.3 Sanofi US Intravenous (IV) Iron Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi US Intravenous (IV) Iron Drugs Product Portfolio
  12. 8.2.5 Sanofi US Recent Developments
  13. 8.3 Pharmacosmos
  14. 8.3.1 Pharmacosmos Company Information
  15. 8.3.2 Pharmacosmos Business Overview
  16. 8.3.3 Pharmacosmos Intravenous (IV) Iron Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Pharmacosmos Intravenous (IV) Iron Drugs Product Portfolio
  18. 8.3.5 Pharmacosmos Recent Developments
  19. 8.4 Luitpold Pharmaceuticals
  20. 8.4.1 Luitpold Pharmaceuticals Company Information
  21. 8.4.2 Luitpold Pharmaceuticals Business Overview
  22. 8.4.3 Luitpold Pharmaceuticals Intravenous (IV) Iron Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Luitpold Pharmaceuticals Intravenous (IV) Iron Drugs Product Portfolio
  24. 8.4.5 Luitpold Pharmaceuticals Recent Developments
  25. 8.5 Dalichi Sankyo
  26. 8.5.1 Dalichi Sankyo Company Information
  27. 8.5.2 Dalichi Sankyo Business Overview
  28. 8.5.3 Dalichi Sankyo Intravenous (IV) Iron Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Dalichi Sankyo Intravenous (IV) Iron Drugs Product Portfolio
  30. 8.5.5 Dalichi Sankyo Recent Developments
  31. 8.6 AMAG Pharmaceuticals
  32. 8.6.1 AMAG Pharmaceuticals Company Information
  33. 8.6.2 AMAG Pharmaceuticals Business Overview
  34. 8.6.3 AMAG Pharmaceuticals Intravenous (IV) Iron Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 AMAG Pharmaceuticals Intravenous (IV) Iron Drugs Product Portfolio
  36. 8.6.5 AMAG Pharmaceuticals Recent Developments
  37. 8.7 Allergan
  38. 8.7.1 Allergan Company Information
  39. 8.7.2 Allergan Business Overview
  40. 8.7.3 Allergan Intravenous (IV) Iron Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Allergan Intravenous (IV) Iron Drugs Product Portfolio
  42. 8.7.5 Allergan Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Intravenous (IV) Iron Drugs Value Chain Analysis
  2. 9.1.1 Intravenous (IV) Iron Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Intravenous (IV) Iron Drugs Production Mode & Process
  6. 9.2 Intravenous (IV) Iron Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Intravenous (IV) Iron Drugs Distributors
  9. 9.2.3 Intravenous (IV) Iron Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst